Gamification in medical knowledge communication: Opportunities for pharma and digital health?

6. May 2026 | B2B, B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD

How can complex medical knowledge be communicated in a way that is not only understood, but also applied in everyday life? This question concerns pharmaceutical companies as well as medical affairs teams and providers of digital health solutions. According to the...

From phase III to real-world care: why the patient perspective matters

1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD

Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...

Digital Therapy Support as a Source of Reliable Patient Insights

4. Mar 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD

What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...

Opening up New Perspectives With Real-World Data and Real-World Evidence

6. Nov 2025 | B2B_Patient_Engagement, B2B_RWD

The digital transformation in healthcare is not only changing the way treatments are developed and marketed – it is also changing how we understand patients. While traditional market research is often based on retrospective data and hypothetical assumptions, digital...